The examination of a patient’s bodily fluids, typically urine or blood, following intrauterine insemination (IUI) to ascertain whether conception has occurred is a standard procedure in assisted reproductive technology. This analysis detects the presence of human chorionic gonadotropin (hCG), a hormone produced after implantation of a fertilized egg. Elevated levels of hCG generally indicate pregnancy. For example, a woman undergoing IUI would schedule this examination approximately two weeks after the procedure to determine its success.
Determining the outcome of IUI is vital for both the patient and the medical team. Early confirmation of pregnancy allows for timely initiation of prenatal care, while a negative result informs subsequent treatment planning. Historically, relying solely on clinical symptoms to determine pregnancy status was unreliable. Therefore, the availability of sensitive hormone assays has revolutionized the process, providing accurate and early detection, thereby improving patient management and outcomes.
